The pathophysiology of heart failure with preserved ejection fraction.
about
The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fractionChallenging aspects of treatment strategies in heart failure with preserved ejection fraction: "Why did recent clinical trials fail?"What can we learn about treating heart failure from the heart's response to acute exercise? Focus on the coronary microcirculationPathophysiology of Heart Failure.Cardiovascular Disease in Women: Clinical Perspectives.Risk factors for heart failure are associated with alterations of the LV end-diastolic pressure-volume relationship in non-heart failure individuals: data from a large-scale, population-based cohort.Pulmonary vascular volume, impaired left ventricular filling and dyspnea: The MESA Lung Study.Targeting Endothelial Function to Treat Heart Failure with Preserved Ejection Fraction: The Promise of Exercise Training.Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunctionEffects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction.Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue.Age, Gender and Load-Related Influences on Left Ventricular Geometric Remodeling, Systolic Mid-Wall Function, and NT-ProBNP in Asymptomatic Asian Population.Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction.Impairment of Coronary Flow Reserve Evaluated by Phase Contrast Cine-Magnetic Resonance Imaging in Patients With Heart Failure With Preserved Ejection FractionDeceleration and acceleration capacities of heart rate associated with heart failure with high discriminating performance.Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Effect of obesity on the effectiveness of cardiac resynchronization to reduce the risk of first and recurrent ventricular tachyarrhythmia events.Mast Cell Inhibition Attenuates Cardiac Remodeling and Diastolic Dysfunction in Middle-aged, Ovariectomized Fischer 344 × Brown Norway Rats.Zooming in on the Microvasculature in Heart Failure With Preserved Ejection Fraction.Effects of renal denervation on vascular remodelling in patients with heart failure and preserved ejection fraction: A randomised control trial.Cardiac myosin binding protein-C Ser302 phosphorylation regulates cardiac β-adrenergic reserveAge-dependent diastolic heart failure in an in vivo Drosophila model.Targeting interleukin-1 in heart failure and inflammatory heart disease.INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design.Low level exercise echocardiography helps diagnose early stage heart failure with preserved ejection fraction: a study of echocardiography versus catheterization.Cell- and molecular-level mechanisms contributing to diastolic dysfunction in HFpEFDiastolic function in heart failure.Heart failure with preserved ejection fraction: uncertainties and dilemmas.Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?Impact of negative inotropic drugs on accuracy of diastolic stress echocardiography for evaluation of left ventricular filling pressure.Obesity, body composition and cardiorespiratory fitness in heart failure with preserved ejection fraction.Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction.Chronic heart failure: Ca(2+), catabolism, and catastrophic cell death.Regional differences in health-related quality of life in elderly heart failure patients: results from the CIBIS-ELD trial.After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction.Translational neurocardiology: preclinical models and cardioneural integrative aspects.Rho Kinases and Cardiac Remodeling.Heart failure with preserved ejection fraction and skeletal muscle physiology.Obesity-induced cardiac lipid accumulation in adult mice is modulated by G protein-coupled receptor kinase 2 levels.Cardiovascular disease risk among women living with HIV in North America and Europe.
P2860
Q26765101-1CBDE2C4-A7F8-431C-A027-9061069BD9CCQ26785931-F5552EA0-96E6-423B-A358-AE05CD47F40DQ28083350-D6D59E35-0F29-4DF8-BBE8-A965B3A97F9CQ30315815-1F4D1DE1-B1EE-4177-9E63-187B91091A7FQ30743765-05936A2E-97B0-446A-A105-9850A90DB6F3Q31071475-676D1D90-A9C9-4D4F-83A9-F1938FAA1452Q33585317-048C1818-6EF1-41D8-8C48-092A1CBB30C4Q33863759-8CF8D52C-7084-406F-8D09-E4FF60F3ED1BQ33877795-1B22387E-42D6-4CA2-B5C4-1DA6F21EBD6BQ35630046-BBEBA9C2-18BE-4FDE-94C0-0D4D8DB47001Q35882942-5BC7548E-ABFC-4784-9270-BC142882486EQ36046811-6687E38B-0A6C-4312-949B-FC180D2078A5Q36266675-9B8EADEE-C0A3-46E9-9389-713BA49B8668Q36713960-97AB75D2-4BD2-4B83-8D0E-B7EDF7C68FE5Q36719531-65B50E76-7844-4D7D-A681-6092C46AF3BAQ37058596-EB047CBD-1C9B-4E77-B950-C33E83074A86Q37073725-C8E9B758-CCCF-45CF-8F5B-AC0BE06BFC31Q37079737-CDEAA8FB-9628-4796-8D94-3BBAE6621F84Q37350630-21C877AA-C7C4-4C71-B07D-C54A387EE161Q37641258-19EB8BD6-7A41-4D14-9393-5BC093A9C2B2Q37693685-13807A9D-5C0F-4078-8337-4E4D83CD3B7BQ37716248-91A6A74F-C037-481D-B37E-18A6551B964AQ38260179-2CDE9265-78B5-4547-87DA-0F0AA1E6B1E0Q38377133-4A3E1132-F31D-43F7-95C4-DA8F99C4F0A6Q38386912-C2113079-3E1D-4A08-B7DF-F3B835A2E28AQ38441801-99D8300D-0BFB-47B0-BB01-BF0B6410AF9AQ38448438-B698C61B-4E2B-4199-BEA6-F2EC3918EEF8Q38529003-3B582987-9B6F-4799-A231-C6F01FD6868BQ38593070-3A925448-5CA4-416C-B903-314E10A83BFFQ38607586-F9BC5D52-12F2-469A-9F1C-8ADDC5F01ACBQ38644526-BB66A68E-AF38-442C-8BB8-B7EB5CF8AE86Q38691846-53F9A28C-A15A-470D-9190-3049D3AACD0FQ38699105-16F26D5F-68D0-4AA6-986C-54A114942578Q38737378-533EAC5D-DE45-48DF-A6F2-71274C6748ABQ38807777-0F09E176-5F23-48C8-B444-30A22640774EQ38813230-D1338A18-1992-49EE-9AD7-9A03ED8534DFQ38850635-DFF368FB-B79B-4737-9AD9-313B7796A1D6Q38931738-B2BF6992-C581-472C-9970-88F590CA17D0Q39198039-08466375-975F-4C20-9608-18D5F8F974FEQ40074176-1BB76E9D-DDE9-4C73-816A-CB2A89D58207
P2860
The pathophysiology of heart failure with preserved ejection fraction.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
The pathophysiology of heart failure with preserved ejection fraction.
@en
type
label
The pathophysiology of heart failure with preserved ejection fraction.
@en
prefLabel
The pathophysiology of heart failure with preserved ejection fraction.
@en
P356
P1476
The pathophysiology of heart failure with preserved ejection fraction
@en
P2093
Barry A Borlaug
P304
P356
10.1038/NRCARDIO.2014.83
P407
P577
2014-06-24T00:00:00Z